nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluoxetine—SIGMAR1—Raloxifene—osteoporosis	0.143	0.215	CbGbCtD
Fluoxetine—ALB—Estropipate—osteoporosis	0.0569	0.0856	CbGbCtD
Fluoxetine—CYP2B6—Raloxifene—osteoporosis	0.0387	0.0583	CbGbCtD
Fluoxetine—CYP2B6—Ethinyl Estradiol—osteoporosis	0.0374	0.0563	CbGbCtD
Fluoxetine—CYP1A2—Estropipate—osteoporosis	0.034	0.0512	CbGbCtD
Fluoxetine—CYP2C9—Estropipate—osteoporosis	0.0307	0.0461	CbGbCtD
Fluoxetine—CYP2B6—Cholecalciferol—osteoporosis	0.0299	0.045	CbGbCtD
Fluoxetine—ALB—Estradiol—osteoporosis	0.0236	0.0355	CbGbCtD
Fluoxetine—ABCB1—Ethinyl Estradiol—osteoporosis	0.0192	0.0288	CbGbCtD
Fluoxetine—CYP2C19—Cholecalciferol—osteoporosis	0.019	0.0286	CbGbCtD
Fluoxetine—CYP3A5—Estradiol—osteoporosis	0.019	0.0286	CbGbCtD
Fluoxetine—CYP3A4—Estropipate—osteoporosis	0.0178	0.0268	CbGbCtD
Fluoxetine—CYP3A4—Calcitriol—osteoporosis	0.0178	0.0268	CbGbCtD
Fluoxetine—CYP1A2—Conjugated Estrogens—osteoporosis	0.0161	0.0242	CbGbCtD
Fluoxetine—CYP2C9—Cholecalciferol—osteoporosis	0.0158	0.0238	CbGbCtD
Fluoxetine—CYP2C19—Estradiol—osteoporosis	0.0153	0.023	CbGbCtD
Fluoxetine—CYP2D6—Cholecalciferol—osteoporosis	0.0144	0.0217	CbGbCtD
Fluoxetine—CYP3A4—Ergocalciferol—osteoporosis	0.0142	0.0214	CbGbCtD
Fluoxetine—CYP1A2—Estradiol—osteoporosis	0.0141	0.0213	CbGbCtD
Fluoxetine—ABCB1—Conjugated Estrogens—osteoporosis	0.0141	0.0212	CbGbCtD
Fluoxetine—CYP2C9—Estradiol—osteoporosis	0.0127	0.0192	CbGbCtD
Fluoxetine—ABCB1—Estradiol—osteoporosis	0.0124	0.0186	CbGbCtD
Fluoxetine—CYP3A4—Raloxifene—osteoporosis	0.0119	0.0179	CbGbCtD
Fluoxetine—CYP3A4—Ethinyl Estradiol—osteoporosis	0.0115	0.0173	CbGbCtD
Fluoxetine—CYP3A4—Cholecalciferol—osteoporosis	0.00918	0.0138	CbGbCtD
Fluoxetine—CYP3A4—Conjugated Estrogens—osteoporosis	0.00843	0.0127	CbGbCtD
Fluoxetine—CYP3A4—Estradiol—osteoporosis	0.0074	0.0111	CbGbCtD
Fluoxetine—SIGMAR1—Levonorgestrel—Ethinyl Estradiol—osteoporosis	0.00188	1	CbGdCrCtD
Fluoxetine—Paraesthesia—Risedronate—osteoporosis	9.93e-05	0.000328	CcSEcCtD
Fluoxetine—Pruritus—Estropipate—osteoporosis	9.9e-05	0.000327	CcSEcCtD
Fluoxetine—Discomfort—Zoledronate—osteoporosis	9.9e-05	0.000327	CcSEcCtD
Fluoxetine—Asthenia—Alendronate—osteoporosis	9.89e-05	0.000327	CcSEcCtD
Fluoxetine—Hypersensitivity—Ibandronate—osteoporosis	9.89e-05	0.000327	CcSEcCtD
Fluoxetine—Cough—Conjugated Estrogens—osteoporosis	9.89e-05	0.000327	CcSEcCtD
Fluoxetine—Dyspnoea—Risedronate—osteoporosis	9.86e-05	0.000326	CcSEcCtD
Fluoxetine—Erythema multiforme—Estradiol—osteoporosis	9.85e-05	0.000326	CcSEcCtD
Fluoxetine—Hypotension—Pamidronate—osteoporosis	9.82e-05	0.000325	CcSEcCtD
Fluoxetine—Convulsion—Conjugated Estrogens—osteoporosis	9.82e-05	0.000324	CcSEcCtD
Fluoxetine—Dry mouth—Zoledronate—osteoporosis	9.8e-05	0.000324	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	9.79e-05	0.000324	CcSEcCtD
Fluoxetine—Fatigue—Ethinyl Estradiol—osteoporosis	9.78e-05	0.000323	CcSEcCtD
Fluoxetine—Pruritus—Alendronate—osteoporosis	9.75e-05	0.000322	CcSEcCtD
Fluoxetine—Dyspepsia—Risedronate—osteoporosis	9.73e-05	0.000322	CcSEcCtD
Fluoxetine—Tinnitus—Estradiol—osteoporosis	9.71e-05	0.000321	CcSEcCtD
Fluoxetine—Constipation—Ethinyl Estradiol—osteoporosis	9.7e-05	0.000321	CcSEcCtD
Fluoxetine—Confusional state—Zoledronate—osteoporosis	9.68e-05	0.00032	CcSEcCtD
Fluoxetine—Hypersensitivity—Calcitriol—osteoporosis	9.68e-05	0.00032	CcSEcCtD
Fluoxetine—Myalgia—Conjugated Estrogens—osteoporosis	9.65e-05	0.000319	CcSEcCtD
Fluoxetine—Arthralgia—Conjugated Estrogens—osteoporosis	9.65e-05	0.000319	CcSEcCtD
Fluoxetine—Chest pain—Conjugated Estrogens—osteoporosis	9.65e-05	0.000319	CcSEcCtD
Fluoxetine—Asthenia—Ibandronate—osteoporosis	9.63e-05	0.000318	CcSEcCtD
Fluoxetine—Anxiety—Conjugated Estrogens—osteoporosis	9.61e-05	0.000318	CcSEcCtD
Fluoxetine—Nausea—Etidronic acid—osteoporosis	9.61e-05	0.000318	CcSEcCtD
Fluoxetine—Anaphylactic shock—Zoledronate—osteoporosis	9.6e-05	0.000317	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	9.58e-05	0.000317	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Pamidronate—osteoporosis	9.58e-05	0.000317	CcSEcCtD
Fluoxetine—Diarrhoea—Estropipate—osteoporosis	9.57e-05	0.000316	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Risedronate—osteoporosis	9.55e-05	0.000316	CcSEcCtD
Fluoxetine—Infection—Zoledronate—osteoporosis	9.54e-05	0.000315	CcSEcCtD
Fluoxetine—Fatigue—Risedronate—osteoporosis	9.53e-05	0.000315	CcSEcCtD
Fluoxetine—Insomnia—Pamidronate—osteoporosis	9.51e-05	0.000314	CcSEcCtD
Fluoxetine—Pruritus—Ibandronate—osteoporosis	9.49e-05	0.000314	CcSEcCtD
Fluoxetine—Pain—Risedronate—osteoporosis	9.46e-05	0.000313	CcSEcCtD
Fluoxetine—Constipation—Risedronate—osteoporosis	9.46e-05	0.000313	CcSEcCtD
Fluoxetine—Shock—Zoledronate—osteoporosis	9.45e-05	0.000312	CcSEcCtD
Fluoxetine—Paraesthesia—Pamidronate—osteoporosis	9.44e-05	0.000312	CcSEcCtD
Fluoxetine—Diarrhoea—Alendronate—osteoporosis	9.43e-05	0.000312	CcSEcCtD
Fluoxetine—Asthenia—Calcitriol—osteoporosis	9.43e-05	0.000312	CcSEcCtD
Fluoxetine—Thrombocytopenia—Zoledronate—osteoporosis	9.4e-05	0.000311	CcSEcCtD
Fluoxetine—Dyspnoea—Pamidronate—osteoporosis	9.37e-05	0.00031	CcSEcCtD
Fluoxetine—Tachycardia—Zoledronate—osteoporosis	9.37e-05	0.00031	CcSEcCtD
Fluoxetine—Feeling abnormal—Ethinyl Estradiol—osteoporosis	9.35e-05	0.000309	CcSEcCtD
Fluoxetine—Chills—Estradiol—osteoporosis	9.35e-05	0.000309	CcSEcCtD
Fluoxetine—Somnolence—Pamidronate—osteoporosis	9.35e-05	0.000309	CcSEcCtD
Fluoxetine—Skin disorder—Zoledronate—osteoporosis	9.33e-05	0.000308	CcSEcCtD
Fluoxetine—Pruritus—Calcitriol—osteoporosis	9.29e-05	0.000307	CcSEcCtD
Fluoxetine—Hyperhidrosis—Zoledronate—osteoporosis	9.28e-05	0.000307	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	9.28e-05	0.000307	CcSEcCtD
Fluoxetine—Diarrhoea—Raloxifene—osteoporosis	9.27e-05	0.000307	CcSEcCtD
Fluoxetine—Dyspepsia—Pamidronate—osteoporosis	9.25e-05	0.000306	CcSEcCtD
Fluoxetine—Dizziness—Estropipate—osteoporosis	9.25e-05	0.000306	CcSEcCtD
Fluoxetine—Anaphylactic shock—Conjugated Estrogens—osteoporosis	9.25e-05	0.000306	CcSEcCtD
Fluoxetine—Alopecia—Estradiol—osteoporosis	9.2e-05	0.000304	CcSEcCtD
Fluoxetine—Infection—Conjugated Estrogens—osteoporosis	9.19e-05	0.000304	CcSEcCtD
Fluoxetine—Diarrhoea—Ibandronate—osteoporosis	9.18e-05	0.000304	CcSEcCtD
Fluoxetine—Anorexia—Zoledronate—osteoporosis	9.15e-05	0.000303	CcSEcCtD
Fluoxetine—Decreased appetite—Pamidronate—osteoporosis	9.14e-05	0.000302	CcSEcCtD
Fluoxetine—Mental disorder—Estradiol—osteoporosis	9.13e-05	0.000302	CcSEcCtD
Fluoxetine—Dizziness—Alendronate—osteoporosis	9.11e-05	0.000301	CcSEcCtD
Fluoxetine—Shock—Conjugated Estrogens—osteoporosis	9.1e-05	0.000301	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Pamidronate—osteoporosis	9.08e-05	0.0003	CcSEcCtD
Fluoxetine—Malnutrition—Estradiol—osteoporosis	9.07e-05	0.0003	CcSEcCtD
Fluoxetine—Fatigue—Pamidronate—osteoporosis	9.06e-05	0.0003	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Risedronate—osteoporosis	9.04e-05	0.000299	CcSEcCtD
Fluoxetine—Tachycardia—Conjugated Estrogens—osteoporosis	9.02e-05	0.000298	CcSEcCtD
Fluoxetine—Urticaria—Ethinyl Estradiol—osteoporosis	9.01e-05	0.000298	CcSEcCtD
Fluoxetine—Pain—Pamidronate—osteoporosis	8.99e-05	0.000297	CcSEcCtD
Fluoxetine—Constipation—Pamidronate—osteoporosis	8.99e-05	0.000297	CcSEcCtD
Fluoxetine—Diarrhoea—Calcitriol—osteoporosis	8.99e-05	0.000297	CcSEcCtD
Fluoxetine—Skin disorder—Conjugated Estrogens—osteoporosis	8.98e-05	0.000297	CcSEcCtD
Fluoxetine—Hypotension—Zoledronate—osteoporosis	8.97e-05	0.000297	CcSEcCtD
Fluoxetine—Abdominal pain—Ethinyl Estradiol—osteoporosis	8.97e-05	0.000296	CcSEcCtD
Fluoxetine—Body temperature increased—Ethinyl Estradiol—osteoporosis	8.97e-05	0.000296	CcSEcCtD
Fluoxetine—Dizziness—Raloxifene—osteoporosis	8.96e-05	0.000296	CcSEcCtD
Fluoxetine—Hyperhidrosis—Conjugated Estrogens—osteoporosis	8.94e-05	0.000295	CcSEcCtD
Fluoxetine—Flatulence—Estradiol—osteoporosis	8.94e-05	0.000295	CcSEcCtD
Fluoxetine—Tension—Estradiol—osteoporosis	8.9e-05	0.000294	CcSEcCtD
Fluoxetine—Vomiting—Estropipate—osteoporosis	8.9e-05	0.000294	CcSEcCtD
Fluoxetine—Dysgeusia—Estradiol—osteoporosis	8.88e-05	0.000294	CcSEcCtD
Fluoxetine—Dizziness—Ibandronate—osteoporosis	8.87e-05	0.000293	CcSEcCtD
Fluoxetine—Rash—Estropipate—osteoporosis	8.82e-05	0.000292	CcSEcCtD
Fluoxetine—Dermatitis—Estropipate—osteoporosis	8.82e-05	0.000291	CcSEcCtD
Fluoxetine—Anorexia—Conjugated Estrogens—osteoporosis	8.81e-05	0.000291	CcSEcCtD
Fluoxetine—Nervousness—Estradiol—osteoporosis	8.81e-05	0.000291	CcSEcCtD
Fluoxetine—Urticaria—Risedronate—osteoporosis	8.79e-05	0.00029	CcSEcCtD
Fluoxetine—Back pain—Estradiol—osteoporosis	8.77e-05	0.00029	CcSEcCtD
Fluoxetine—Headache—Estropipate—osteoporosis	8.77e-05	0.00029	CcSEcCtD
Fluoxetine—Vomiting—Alendronate—osteoporosis	8.76e-05	0.00029	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Zoledronate—osteoporosis	8.75e-05	0.000289	CcSEcCtD
Fluoxetine—Abdominal pain—Risedronate—osteoporosis	8.74e-05	0.000289	CcSEcCtD
Fluoxetine—Body temperature increased—Risedronate—osteoporosis	8.74e-05	0.000289	CcSEcCtD
Fluoxetine—Muscle spasms—Estradiol—osteoporosis	8.72e-05	0.000288	CcSEcCtD
Fluoxetine—Rash—Alendronate—osteoporosis	8.69e-05	0.000287	CcSEcCtD
Fluoxetine—Insomnia—Zoledronate—osteoporosis	8.69e-05	0.000287	CcSEcCtD
Fluoxetine—Dermatitis—Alendronate—osteoporosis	8.68e-05	0.000287	CcSEcCtD
Fluoxetine—Feeling abnormal—Pamidronate—osteoporosis	8.66e-05	0.000286	CcSEcCtD
Fluoxetine—Hypotension—Conjugated Estrogens—osteoporosis	8.64e-05	0.000286	CcSEcCtD
Fluoxetine—Headache—Alendronate—osteoporosis	8.63e-05	0.000285	CcSEcCtD
Fluoxetine—Paraesthesia—Zoledronate—osteoporosis	8.62e-05	0.000285	CcSEcCtD
Fluoxetine—Vomiting—Raloxifene—osteoporosis	8.62e-05	0.000285	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Pamidronate—osteoporosis	8.6e-05	0.000284	CcSEcCtD
Fluoxetine—Dyspnoea—Zoledronate—osteoporosis	8.56e-05	0.000283	CcSEcCtD
Fluoxetine—Rash—Raloxifene—osteoporosis	8.55e-05	0.000283	CcSEcCtD
Fluoxetine—Dermatitis—Raloxifene—osteoporosis	8.54e-05	0.000282	CcSEcCtD
Fluoxetine—Somnolence—Zoledronate—osteoporosis	8.54e-05	0.000282	CcSEcCtD
Fluoxetine—Vomiting—Ibandronate—osteoporosis	8.53e-05	0.000282	CcSEcCtD
Fluoxetine—Tremor—Estradiol—osteoporosis	8.5e-05	0.000281	CcSEcCtD
Fluoxetine—Headache—Raloxifene—osteoporosis	8.49e-05	0.000281	CcSEcCtD
Fluoxetine—Rash—Ibandronate—osteoporosis	8.46e-05	0.00028	CcSEcCtD
Fluoxetine—Dermatitis—Ibandronate—osteoporosis	8.45e-05	0.000279	CcSEcCtD
Fluoxetine—Dyspepsia—Zoledronate—osteoporosis	8.45e-05	0.000279	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	8.42e-05	0.000278	CcSEcCtD
Fluoxetine—Ill-defined disorder—Estradiol—osteoporosis	8.41e-05	0.000278	CcSEcCtD
Fluoxetine—Headache—Ibandronate—osteoporosis	8.41e-05	0.000278	CcSEcCtD
Fluoxetine—Insomnia—Conjugated Estrogens—osteoporosis	8.36e-05	0.000276	CcSEcCtD
Fluoxetine—Hypersensitivity—Ethinyl Estradiol—osteoporosis	8.36e-05	0.000276	CcSEcCtD
Fluoxetine—Vomiting—Calcitriol—osteoporosis	8.35e-05	0.000276	CcSEcCtD
Fluoxetine—Decreased appetite—Zoledronate—osteoporosis	8.35e-05	0.000276	CcSEcCtD
Fluoxetine—Agitation—Estradiol—osteoporosis	8.33e-05	0.000275	CcSEcCtD
Fluoxetine—Nausea—Estropipate—osteoporosis	8.31e-05	0.000275	CcSEcCtD
Fluoxetine—Abdominal pain—Pamidronate—osteoporosis	8.31e-05	0.000275	CcSEcCtD
Fluoxetine—Body temperature increased—Pamidronate—osteoporosis	8.31e-05	0.000275	CcSEcCtD
Fluoxetine—Paraesthesia—Conjugated Estrogens—osteoporosis	8.3e-05	0.000274	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Zoledronate—osteoporosis	8.29e-05	0.000274	CcSEcCtD
Fluoxetine—Angioedema—Estradiol—osteoporosis	8.29e-05	0.000274	CcSEcCtD
Fluoxetine—Rash—Calcitriol—osteoporosis	8.28e-05	0.000274	CcSEcCtD
Fluoxetine—Fatigue—Zoledronate—osteoporosis	8.28e-05	0.000274	CcSEcCtD
Fluoxetine—Dermatitis—Calcitriol—osteoporosis	8.28e-05	0.000274	CcSEcCtD
Fluoxetine—Dyspnoea—Conjugated Estrogens—osteoporosis	8.24e-05	0.000272	CcSEcCtD
Fluoxetine—Headache—Calcitriol—osteoporosis	8.23e-05	0.000272	CcSEcCtD
Fluoxetine—Somnolence—Conjugated Estrogens—osteoporosis	8.22e-05	0.000272	CcSEcCtD
Fluoxetine—Pain—Zoledronate—osteoporosis	8.21e-05	0.000271	CcSEcCtD
Fluoxetine—Constipation—Zoledronate—osteoporosis	8.21e-05	0.000271	CcSEcCtD
Fluoxetine—Nausea—Alendronate—osteoporosis	8.19e-05	0.000271	CcSEcCtD
Fluoxetine—Malaise—Estradiol—osteoporosis	8.18e-05	0.00027	CcSEcCtD
Fluoxetine—Hypersensitivity—Risedronate—osteoporosis	8.15e-05	0.000269	CcSEcCtD
Fluoxetine—Vertigo—Estradiol—osteoporosis	8.15e-05	0.000269	CcSEcCtD
Fluoxetine—Dyspepsia—Conjugated Estrogens—osteoporosis	8.14e-05	0.000269	CcSEcCtD
Fluoxetine—Asthenia—Ethinyl Estradiol—osteoporosis	8.14e-05	0.000269	CcSEcCtD
Fluoxetine—Syncope—Estradiol—osteoporosis	8.13e-05	0.000269	CcSEcCtD
Fluoxetine—Nausea—Raloxifene—osteoporosis	8.05e-05	0.000266	CcSEcCtD
Fluoxetine—Decreased appetite—Conjugated Estrogens—osteoporosis	8.04e-05	0.000266	CcSEcCtD
Fluoxetine—Pruritus—Ethinyl Estradiol—osteoporosis	8.03e-05	0.000265	CcSEcCtD
Fluoxetine—Palpitations—Estradiol—osteoporosis	8.01e-05	0.000265	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	7.98e-05	0.000264	CcSEcCtD
Fluoxetine—Fatigue—Conjugated Estrogens—osteoporosis	7.97e-05	0.000264	CcSEcCtD
Fluoxetine—Nausea—Ibandronate—osteoporosis	7.97e-05	0.000263	CcSEcCtD
Fluoxetine—Loss of consciousness—Estradiol—osteoporosis	7.97e-05	0.000263	CcSEcCtD
Fluoxetine—Asthenia—Risedronate—osteoporosis	7.93e-05	0.000262	CcSEcCtD
Fluoxetine—Feeling abnormal—Zoledronate—osteoporosis	7.91e-05	0.000262	CcSEcCtD
Fluoxetine—Cough—Estradiol—osteoporosis	7.91e-05	0.000262	CcSEcCtD
Fluoxetine—Pain—Conjugated Estrogens—osteoporosis	7.91e-05	0.000261	CcSEcCtD
Fluoxetine—Constipation—Conjugated Estrogens—osteoporosis	7.91e-05	0.000261	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Zoledronate—osteoporosis	7.85e-05	0.00026	CcSEcCtD
Fluoxetine—Hypertension—Estradiol—osteoporosis	7.83e-05	0.000259	CcSEcCtD
Fluoxetine—Pruritus—Risedronate—osteoporosis	7.82e-05	0.000259	CcSEcCtD
Fluoxetine—Nausea—Calcitriol—osteoporosis	7.8e-05	0.000258	CcSEcCtD
Fluoxetine—Diarrhoea—Ethinyl Estradiol—osteoporosis	7.76e-05	0.000257	CcSEcCtD
Fluoxetine—Hypersensitivity—Pamidronate—osteoporosis	7.75e-05	0.000256	CcSEcCtD
Fluoxetine—Myalgia—Estradiol—osteoporosis	7.72e-05	0.000255	CcSEcCtD
Fluoxetine—Chest pain—Estradiol—osteoporosis	7.72e-05	0.000255	CcSEcCtD
Fluoxetine—Arthralgia—Estradiol—osteoporosis	7.72e-05	0.000255	CcSEcCtD
Fluoxetine—Anxiety—Estradiol—osteoporosis	7.69e-05	0.000254	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	7.67e-05	0.000253	CcSEcCtD
Fluoxetine—Urticaria—Zoledronate—osteoporosis	7.63e-05	0.000252	CcSEcCtD
Fluoxetine—Discomfort—Estradiol—osteoporosis	7.63e-05	0.000252	CcSEcCtD
Fluoxetine—Body temperature increased—Zoledronate—osteoporosis	7.59e-05	0.000251	CcSEcCtD
Fluoxetine—Abdominal pain—Zoledronate—osteoporosis	7.59e-05	0.000251	CcSEcCtD
Fluoxetine—Diarrhoea—Risedronate—osteoporosis	7.57e-05	0.00025	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	7.56e-05	0.00025	CcSEcCtD
Fluoxetine—Dry mouth—Estradiol—osteoporosis	7.55e-05	0.00025	CcSEcCtD
Fluoxetine—Asthenia—Pamidronate—osteoporosis	7.54e-05	0.000249	CcSEcCtD
Fluoxetine—Dizziness—Ethinyl Estradiol—osteoporosis	7.5e-05	0.000248	CcSEcCtD
Fluoxetine—Confusional state—Estradiol—osteoporosis	7.46e-05	0.000247	CcSEcCtD
Fluoxetine—Pruritus—Pamidronate—osteoporosis	7.44e-05	0.000246	CcSEcCtD
Fluoxetine—Anaphylactic shock—Estradiol—osteoporosis	7.4e-05	0.000245	CcSEcCtD
Fluoxetine—Infection—Estradiol—osteoporosis	7.35e-05	0.000243	CcSEcCtD
Fluoxetine—Urticaria—Conjugated Estrogens—osteoporosis	7.35e-05	0.000243	CcSEcCtD
Fluoxetine—Dizziness—Risedronate—osteoporosis	7.31e-05	0.000242	CcSEcCtD
Fluoxetine—Body temperature increased—Conjugated Estrogens—osteoporosis	7.31e-05	0.000242	CcSEcCtD
Fluoxetine—Abdominal pain—Conjugated Estrogens—osteoporosis	7.31e-05	0.000242	CcSEcCtD
Fluoxetine—Shock—Estradiol—osteoporosis	7.28e-05	0.000241	CcSEcCtD
Fluoxetine—Tachycardia—Estradiol—osteoporosis	7.22e-05	0.000239	CcSEcCtD
Fluoxetine—Vomiting—Ethinyl Estradiol—osteoporosis	7.21e-05	0.000238	CcSEcCtD
Fluoxetine—Diarrhoea—Pamidronate—osteoporosis	7.19e-05	0.000238	CcSEcCtD
Fluoxetine—Skin disorder—Estradiol—osteoporosis	7.19e-05	0.000238	CcSEcCtD
Fluoxetine—Hyperhidrosis—Estradiol—osteoporosis	7.15e-05	0.000236	CcSEcCtD
Fluoxetine—Rash—Ethinyl Estradiol—osteoporosis	7.15e-05	0.000236	CcSEcCtD
Fluoxetine—Dermatitis—Ethinyl Estradiol—osteoporosis	7.15e-05	0.000236	CcSEcCtD
Fluoxetine—Headache—Ethinyl Estradiol—osteoporosis	7.11e-05	0.000235	CcSEcCtD
Fluoxetine—Hypersensitivity—Zoledronate—osteoporosis	7.08e-05	0.000234	CcSEcCtD
Fluoxetine—Vomiting—Risedronate—osteoporosis	7.03e-05	0.000232	CcSEcCtD
Fluoxetine—Rash—Risedronate—osteoporosis	6.97e-05	0.00023	CcSEcCtD
Fluoxetine—Dermatitis—Risedronate—osteoporosis	6.97e-05	0.00023	CcSEcCtD
Fluoxetine—Dizziness—Pamidronate—osteoporosis	6.95e-05	0.00023	CcSEcCtD
Fluoxetine—Headache—Risedronate—osteoporosis	6.93e-05	0.000229	CcSEcCtD
Fluoxetine—Asthenia—Zoledronate—osteoporosis	6.89e-05	0.000228	CcSEcCtD
Fluoxetine—Hypersensitivity—Conjugated Estrogens—osteoporosis	6.81e-05	0.000225	CcSEcCtD
Fluoxetine—Pruritus—Zoledronate—osteoporosis	6.79e-05	0.000225	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Estradiol—osteoporosis	6.74e-05	0.000223	CcSEcCtD
Fluoxetine—Nausea—Ethinyl Estradiol—osteoporosis	6.74e-05	0.000223	CcSEcCtD
Fluoxetine—Insomnia—Estradiol—osteoporosis	6.69e-05	0.000221	CcSEcCtD
Fluoxetine—Vomiting—Pamidronate—osteoporosis	6.68e-05	0.000221	CcSEcCtD
Fluoxetine—Paraesthesia—Estradiol—osteoporosis	6.65e-05	0.00022	CcSEcCtD
Fluoxetine—Asthenia—Conjugated Estrogens—osteoporosis	6.63e-05	0.000219	CcSEcCtD
Fluoxetine—Rash—Pamidronate—osteoporosis	6.63e-05	0.000219	CcSEcCtD
Fluoxetine—Dermatitis—Pamidronate—osteoporosis	6.62e-05	0.000219	CcSEcCtD
Fluoxetine—Dyspnoea—Estradiol—osteoporosis	6.6e-05	0.000218	CcSEcCtD
Fluoxetine—Headache—Pamidronate—osteoporosis	6.59e-05	0.000218	CcSEcCtD
Fluoxetine—Somnolence—Estradiol—osteoporosis	6.58e-05	0.000217	CcSEcCtD
Fluoxetine—Diarrhoea—Zoledronate—osteoporosis	6.57e-05	0.000217	CcSEcCtD
Fluoxetine—Nausea—Risedronate—osteoporosis	6.57e-05	0.000217	CcSEcCtD
Fluoxetine—Pruritus—Conjugated Estrogens—osteoporosis	6.54e-05	0.000216	CcSEcCtD
Fluoxetine—Dyspepsia—Estradiol—osteoporosis	6.51e-05	0.000215	CcSEcCtD
Fluoxetine—Decreased appetite—Estradiol—osteoporosis	6.43e-05	0.000213	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Estradiol—osteoporosis	6.39e-05	0.000211	CcSEcCtD
Fluoxetine—Fatigue—Estradiol—osteoporosis	6.38e-05	0.000211	CcSEcCtD
Fluoxetine—Dizziness—Zoledronate—osteoporosis	6.35e-05	0.00021	CcSEcCtD
Fluoxetine—Constipation—Estradiol—osteoporosis	6.33e-05	0.000209	CcSEcCtD
Fluoxetine—Pain—Estradiol—osteoporosis	6.33e-05	0.000209	CcSEcCtD
Fluoxetine—Diarrhoea—Conjugated Estrogens—osteoporosis	6.33e-05	0.000209	CcSEcCtD
Fluoxetine—Nausea—Pamidronate—osteoporosis	6.24e-05	0.000206	CcSEcCtD
Fluoxetine—Dizziness—Conjugated Estrogens—osteoporosis	6.11e-05	0.000202	CcSEcCtD
Fluoxetine—Vomiting—Zoledronate—osteoporosis	6.11e-05	0.000202	CcSEcCtD
Fluoxetine—Feeling abnormal—Estradiol—osteoporosis	6.1e-05	0.000202	CcSEcCtD
Fluoxetine—Rash—Zoledronate—osteoporosis	6.05e-05	0.0002	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Estradiol—osteoporosis	6.05e-05	0.0002	CcSEcCtD
Fluoxetine—Dermatitis—Zoledronate—osteoporosis	6.05e-05	0.0002	CcSEcCtD
Fluoxetine—Headache—Zoledronate—osteoporosis	6.02e-05	0.000199	CcSEcCtD
Fluoxetine—Vomiting—Conjugated Estrogens—osteoporosis	5.88e-05	0.000194	CcSEcCtD
Fluoxetine—Urticaria—Estradiol—osteoporosis	5.88e-05	0.000194	CcSEcCtD
Fluoxetine—Abdominal pain—Estradiol—osteoporosis	5.85e-05	0.000193	CcSEcCtD
Fluoxetine—Body temperature increased—Estradiol—osteoporosis	5.85e-05	0.000193	CcSEcCtD
Fluoxetine—Rash—Conjugated Estrogens—osteoporosis	5.83e-05	0.000193	CcSEcCtD
Fluoxetine—Dermatitis—Conjugated Estrogens—osteoporosis	5.82e-05	0.000193	CcSEcCtD
Fluoxetine—Headache—Conjugated Estrogens—osteoporosis	5.79e-05	0.000191	CcSEcCtD
Fluoxetine—Nausea—Zoledronate—osteoporosis	5.7e-05	0.000189	CcSEcCtD
Fluoxetine—Nausea—Conjugated Estrogens—osteoporosis	5.49e-05	0.000182	CcSEcCtD
Fluoxetine—Hypersensitivity—Estradiol—osteoporosis	5.45e-05	0.00018	CcSEcCtD
Fluoxetine—Asthenia—Estradiol—osteoporosis	5.31e-05	0.000176	CcSEcCtD
Fluoxetine—Pruritus—Estradiol—osteoporosis	5.24e-05	0.000173	CcSEcCtD
Fluoxetine—Diarrhoea—Estradiol—osteoporosis	5.06e-05	0.000167	CcSEcCtD
Fluoxetine—Dizziness—Estradiol—osteoporosis	4.89e-05	0.000162	CcSEcCtD
Fluoxetine—Vomiting—Estradiol—osteoporosis	4.71e-05	0.000156	CcSEcCtD
Fluoxetine—Rash—Estradiol—osteoporosis	4.67e-05	0.000154	CcSEcCtD
Fluoxetine—Dermatitis—Estradiol—osteoporosis	4.66e-05	0.000154	CcSEcCtD
Fluoxetine—Headache—Estradiol—osteoporosis	4.64e-05	0.000153	CcSEcCtD
Fluoxetine—Nausea—Estradiol—osteoporosis	4.4e-05	0.000145	CcSEcCtD
Fluoxetine—ALB—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	1.7e-05	0.000549	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—CYP27A1—osteoporosis	1.67e-05	0.00054	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—ACP5—osteoporosis	1.67e-05	0.000538	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—GPD2—osteoporosis	1.66e-05	0.000537	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PGLS—osteoporosis	1.66e-05	0.000537	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—OXCT1—osteoporosis	1.66e-05	0.000536	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—CA2—osteoporosis	1.66e-05	0.000536	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—TLN1—osteoporosis	1.66e-05	0.000534	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—P4HB—osteoporosis	1.64e-05	0.000531	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—ACP5—osteoporosis	1.63e-05	0.000526	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—CA2—osteoporosis	1.62e-05	0.000523	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—OXCT1—osteoporosis	1.62e-05	0.000523	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—MGLL—osteoporosis	1.62e-05	0.000522	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PTH—osteoporosis	1.6e-05	0.000516	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—MGLL—osteoporosis	1.58e-05	0.00051	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—RAP1A—osteoporosis	1.57e-05	0.000507	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CNR2—osteoporosis	1.56e-05	0.000503	CbGpPWpGaD
Fluoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—osteoporosis	1.55e-05	0.000501	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—TPI1—osteoporosis	1.55e-05	0.0005	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—ADCY5—osteoporosis	1.55e-05	0.000499	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—IDH2—osteoporosis	1.53e-05	0.000495	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—NFATC1—osteoporosis	1.53e-05	0.000495	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—CA2—osteoporosis	1.53e-05	0.000493	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—OXCT1—osteoporosis	1.53e-05	0.000493	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	1.53e-05	0.000493	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PNP—osteoporosis	1.52e-05	0.000491	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—ATIC—osteoporosis	1.52e-05	0.000491	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—DKK1—osteoporosis	1.52e-05	0.000491	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—CA2—osteoporosis	1.51e-05	0.000489	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—OXCT1—osteoporosis	1.51e-05	0.000489	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—TPI1—osteoporosis	1.51e-05	0.000489	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—MGLL—osteoporosis	1.49e-05	0.000481	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—MGLL—osteoporosis	1.48e-05	0.000476	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—WNT1—osteoporosis	1.47e-05	0.000473	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—P4HB—osteoporosis	1.46e-05	0.00047	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—CYP27A1—osteoporosis	1.44e-05	0.000465	CbGpPWpGaD
Fluoxetine—CYP3A4—Biological oxidations—POMC—osteoporosis	1.44e-05	0.000464	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—GAPDH—osteoporosis	1.43e-05	0.000461	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—P4HB—osteoporosis	1.43e-05	0.000461	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—FGA—osteoporosis	1.43e-05	0.00046	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—P4HB—osteoporosis	1.42e-05	0.000459	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—ADCY5—osteoporosis	1.4e-05	0.000453	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—ACP5—osteoporosis	1.4e-05	0.000453	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—GAPDH—osteoporosis	1.4e-05	0.000451	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—RAP1A—osteoporosis	1.39e-05	0.000449	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	1.39e-05	0.000449	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PTH—osteoporosis	1.39e-05	0.000448	CbGpPWpGaD
Fluoxetine—ALB—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	1.38e-05	0.000447	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—IDH2—osteoporosis	1.38e-05	0.000444	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—RAP1A—osteoporosis	1.36e-05	0.00044	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—RAP1A—osteoporosis	1.36e-05	0.000439	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—FDPS—osteoporosis	1.35e-05	0.000437	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PKM—osteoporosis	1.35e-05	0.000437	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CNR2—osteoporosis	1.35e-05	0.000437	CbGpPWpGaD
Fluoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—osteoporosis	1.35e-05	0.000435	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—IDH2—osteoporosis	1.34e-05	0.000434	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—ADCY5—osteoporosis	1.34e-05	0.000433	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—NFATC1—osteoporosis	1.33e-05	0.00043	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PTHLH—osteoporosis	1.33e-05	0.000428	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—BMP2—osteoporosis	1.33e-05	0.000428	CbGpPWpGaD
Fluoxetine—ALB—Transmembrane transport of small molecules—ADCY5—osteoporosis	1.32e-05	0.000426	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—DKK1—osteoporosis	1.32e-05	0.000426	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—TPI1—osteoporosis	1.3e-05	0.000421	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—FGB—osteoporosis	1.3e-05	0.000418	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—OXCT1—osteoporosis	1.29e-05	0.000418	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—CA2—osteoporosis	1.29e-05	0.000418	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—CYP27A1—osteoporosis	1.29e-05	0.000418	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PGLS—osteoporosis	1.28e-05	0.000415	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—GPD2—osteoporosis	1.28e-05	0.000415	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—WNT1—osteoporosis	1.27e-05	0.000411	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—IDH2—osteoporosis	1.27e-05	0.000409	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—CYP27A1—osteoporosis	1.26e-05	0.000408	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—MGLL—osteoporosis	1.26e-05	0.000407	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—ACP5—osteoporosis	1.26e-05	0.000406	CbGpPWpGaD
Fluoxetine—ALB—Platelet activation, signaling and aggregation—TGFB1—osteoporosis	1.26e-05	0.000405	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—IDH2—osteoporosis	1.26e-05	0.000405	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PSMA2—osteoporosis	1.25e-05	0.000404	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PSMA5—osteoporosis	1.25e-05	0.000404	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	1.24e-05	0.000401	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	1.24e-05	0.0004	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—FGA—osteoporosis	1.24e-05	0.000399	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	1.24e-05	0.000399	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—ACP5—osteoporosis	1.23e-05	0.000397	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—P4HB—osteoporosis	1.23e-05	0.000396	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—ADCY5—osteoporosis	1.22e-05	0.000394	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—GAPDH—osteoporosis	1.2e-05	0.000388	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—CYP27A1—osteoporosis	1.19e-05	0.000384	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	1.19e-05	0.000384	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—CYP27A1—osteoporosis	1.18e-05	0.000381	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ATIC—osteoporosis	1.17e-05	0.000379	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PNP—osteoporosis	1.17e-05	0.000379	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—RAP1A—osteoporosis	1.17e-05	0.000378	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—TPI1—osteoporosis	1.17e-05	0.000378	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CALCA—osteoporosis	1.17e-05	0.000376	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—ACP5—osteoporosis	1.16e-05	0.000374	CbGpPWpGaD
Fluoxetine—ABCB1—Transmembrane transport of small molecules—ADCY5—osteoporosis	1.16e-05	0.000374	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	1.15e-05	0.000373	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—BMP2—osteoporosis	1.15e-05	0.000371	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PTHLH—osteoporosis	1.15e-05	0.000371	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—ACP5—osteoporosis	1.15e-05	0.00037	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—TPI1—osteoporosis	1.14e-05	0.000369	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—POMC—osteoporosis	1.14e-05	0.000367	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	1.13e-05	0.000366	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—FGB—osteoporosis	1.13e-05	0.000363	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—ENO1—osteoporosis	1.13e-05	0.000363	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PSMA5—osteoporosis	1.11e-05	0.000358	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PSMA2—osteoporosis	1.11e-05	0.000358	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—P4HB—osteoporosis	1.1e-05	0.000355	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—ENO1—osteoporosis	1.1e-05	0.000355	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PSMA2—osteoporosis	1.09e-05	0.000351	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PSMA5—osteoporosis	1.09e-05	0.000351	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PSMA2—osteoporosis	1.08e-05	0.00035	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PSMA5—osteoporosis	1.08e-05	0.00035	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—GAPDH—osteoporosis	1.08e-05	0.000349	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—IGF1—osteoporosis	1.08e-05	0.000348	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—TPI1—osteoporosis	1.08e-05	0.000347	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—P4HB—osteoporosis	1.07e-05	0.000347	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—IDH2—osteoporosis	1.07e-05	0.000346	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—TPI1—osteoporosis	1.07e-05	0.000344	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—KL—osteoporosis	1.06e-05	0.000342	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—GAPDH—osteoporosis	1.05e-05	0.00034	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—RAP1A—osteoporosis	1.05e-05	0.000339	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—POMC—osteoporosis	1.03e-05	0.000333	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—RAP1A—osteoporosis	1.03e-05	0.000331	CbGpPWpGaD
Fluoxetine—ALB—Metabolism of lipids and lipoproteins—POMC—osteoporosis	1.02e-05	0.00033	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CALCA—osteoporosis	1.01e-05	0.000327	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—P4HB—osteoporosis	1.01e-05	0.000327	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—CYP27A1—osteoporosis	1.01e-05	0.000325	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—IL6R—osteoporosis	1.01e-05	0.000325	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—P4HB—osteoporosis	1e-05	0.000324	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—OXCT1—osteoporosis	9.99e-06	0.000322	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CA2—osteoporosis	9.99e-06	0.000322	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—GAPDH—osteoporosis	9.93e-06	0.000321	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—POMC—osteoporosis	9.88e-06	0.000319	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—GAPDH—osteoporosis	9.85e-06	0.000318	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—ACP5—osteoporosis	9.81e-06	0.000317	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—MGLL—osteoporosis	9.73e-06	0.000314	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	9.68e-06	0.000313	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—RAP1A—osteoporosis	9.68e-06	0.000312	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—RAP1A—osteoporosis	9.59e-06	0.00031	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—ENO1—osteoporosis	9.47e-06	0.000306	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PSMA2—osteoporosis	9.33e-06	0.000301	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PSMA5—osteoporosis	9.33e-06	0.000301	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—KL—osteoporosis	9.2e-06	0.000297	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—POMC—osteoporosis	9.17e-06	0.000296	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—TPI1—osteoporosis	9.12e-06	0.000294	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—CYP19A1—osteoporosis	9e-06	0.00029	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—POMC—osteoporosis	8.97e-06	0.00029	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—CYP19A1—osteoporosis	8.79e-06	0.000284	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—IL6R—osteoporosis	8.75e-06	0.000282	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—P4HB—osteoporosis	8.57e-06	0.000277	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—ENO1—osteoporosis	8.5e-06	0.000274	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—GAPDH—osteoporosis	8.42e-06	0.000272	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PSMA2—osteoporosis	8.38e-06	0.00027	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PSMA5—osteoporosis	8.38e-06	0.00027	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—POMC—osteoporosis	8.36e-06	0.00027	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—ENO1—osteoporosis	8.3e-06	0.000268	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—ADCY5—osteoporosis	8.3e-06	0.000268	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—IDH2—osteoporosis	8.28e-06	0.000267	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—RAP1A—osteoporosis	8.2e-06	0.000265	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PSMA2—osteoporosis	8.18e-06	0.000264	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PSMA5—osteoporosis	8.18e-06	0.000264	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—SPP1—osteoporosis	8.03e-06	0.000259	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—ENO1—osteoporosis	7.82e-06	0.000252	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CYP27A1—osteoporosis	7.78e-06	0.000251	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—ENO1—osteoporosis	7.75e-06	0.00025	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PSMA5—osteoporosis	7.71e-06	0.000249	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PSMA2—osteoporosis	7.71e-06	0.000249	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PSMA5—osteoporosis	7.64e-06	0.000247	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PSMA2—osteoporosis	7.64e-06	0.000247	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—CYP19A1—osteoporosis	7.57e-06	0.000244	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ACP5—osteoporosis	7.57e-06	0.000244	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—ADCY5—osteoporosis	7.35e-06	0.000237	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—GPX1—osteoporosis	7.33e-06	0.000236	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—IRS2—osteoporosis	7.26e-06	0.000234	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—ADCY5—osteoporosis	7.21e-06	0.000233	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—ADCY5—osteoporosis	7.18e-06	0.000232	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—GPX1—osteoporosis	7.16e-06	0.000231	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—POMC—osteoporosis	7.15e-06	0.000231	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—LEP—osteoporosis	7.11e-06	0.000229	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—TPI1—osteoporosis	7.04e-06	0.000227	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—SPP1—osteoporosis	6.97e-06	0.000225	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—CYP19A1—osteoporosis	6.8e-06	0.000219	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—ESR1—osteoporosis	6.78e-06	0.000219	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—MTHFR—osteoporosis	6.76e-06	0.000218	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—CYP19A1—osteoporosis	6.64e-06	0.000214	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—ENO1—osteoporosis	6.63e-06	0.000214	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—P4HB—osteoporosis	6.62e-06	0.000214	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—MTHFR—osteoporosis	6.61e-06	0.000213	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PSMA2—osteoporosis	6.53e-06	0.000211	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PSMA5—osteoporosis	6.53e-06	0.000211	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—GAPDH—osteoporosis	6.5e-06	0.00021	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—TGFB1—osteoporosis	6.47e-06	0.000209	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—IRS1—osteoporosis	6.34e-06	0.000205	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—RAP1A—osteoporosis	6.33e-06	0.000204	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—IRS2—osteoporosis	6.3e-06	0.000203	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—CYP19A1—osteoporosis	6.25e-06	0.000202	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—CYP19A1—osteoporosis	6.2e-06	0.0002	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—ADCY5—osteoporosis	6.19e-06	0.0002	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—LEP—osteoporosis	6.17e-06	0.000199	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—GPX1—osteoporosis	6.17e-06	0.000199	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—POMC—osteoporosis	6.1e-06	0.000197	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—IL6R—osteoporosis	5.95e-06	0.000192	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—ESR1—osteoporosis	5.89e-06	0.00019	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—IGF1—osteoporosis	5.87e-06	0.000189	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—MTHFR—osteoporosis	5.69e-06	0.000184	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—ADCY5—osteoporosis	5.55e-06	0.000179	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—GPX1—osteoporosis	5.54e-06	0.000179	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—IRS1—osteoporosis	5.5e-06	0.000178	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—ADCY5—osteoporosis	5.42e-06	0.000175	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—POMC—osteoporosis	5.41e-06	0.000174	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—GPX1—osteoporosis	5.4e-06	0.000174	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—POMC—osteoporosis	5.3e-06	0.000171	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—CYP19A1—osteoporosis	5.3e-06	0.000171	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—POMC—osteoporosis	5.28e-06	0.000171	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—IL6R—osteoporosis	5.17e-06	0.000167	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ENO1—osteoporosis	5.11e-06	0.000165	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—ADCY5—osteoporosis	5.11e-06	0.000165	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—MTHFR—osteoporosis	5.11e-06	0.000165	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—IGF1—osteoporosis	5.1e-06	0.000165	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—GPX1—osteoporosis	5.09e-06	0.000164	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—ADCY5—osteoporosis	5.06e-06	0.000163	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—GPX1—osteoporosis	5.05e-06	0.000163	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PSMA2—osteoporosis	5.04e-06	0.000163	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PSMA5—osteoporosis	5.04e-06	0.000163	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—MTHFR—osteoporosis	4.99e-06	0.000161	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—MTHFR—osteoporosis	4.7e-06	0.000152	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—MTHFR—osteoporosis	4.66e-06	0.00015	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—POMC—osteoporosis	4.55e-06	0.000147	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—IL6—osteoporosis	4.49e-06	0.000145	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—ADCY5—osteoporosis	4.33e-06	0.00014	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—GPX1—osteoporosis	4.31e-06	0.000139	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CYP19A1—osteoporosis	4.09e-06	0.000132	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—POMC—osteoporosis	4.09e-06	0.000132	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—POMC—osteoporosis	3.99e-06	0.000129	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—MTHFR—osteoporosis	3.98e-06	0.000128	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—IL6—osteoporosis	3.9e-06	0.000126	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—POMC—osteoporosis	3.76e-06	0.000121	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—POMC—osteoporosis	3.73e-06	0.00012	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MYC—osteoporosis	3.53e-06	0.000114	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—TGFB1—osteoporosis	3.52e-06	0.000114	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ADCY5—osteoporosis	3.34e-06	0.000108	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—GPX1—osteoporosis	3.33e-06	0.000107	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—POMC—osteoporosis	3.18e-06	0.000103	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—MTHFR—osteoporosis	3.07e-06	9.91e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MYC—osteoporosis	3.06e-06	9.89e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—TGFB1—osteoporosis	3.06e-06	9.86e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—IL6—osteoporosis	2.65e-06	8.56e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—POMC—osteoporosis	2.46e-06	7.93e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—IL6—osteoporosis	2.3e-06	7.43e-05	CbGpPWpGaD
